SequelSEC

BIOMERICA INC BMRA

In Vitro & In Vivo Diagnostic Substances · CIK 0000073290 · Fiscal year ends 0531

AnnualQuarterlyTTM
Revenue
$4.34M
Fiscal year ended 2026-08-31
Operating income
-$5.43M
Fiscal year ended 2026-08-31
Free cash flow
Unavailable
Fiscal year ended 2026-08-31

Valuation, from the filing

Public float$6.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-11-28
Float per share$1.44Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.5×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity2.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-11-28, not today, and each multiple below it uses the figures for the fiscal year ending 2026-05-31 — the year that filing covered.

How this compares in its industry

Percentile among the In Vitro & In Vivo Diagnostic Substances filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin8.1%0th
Revenue YoY growth-16.2%14th
Current ratio1.62x33th
Net margin-84.8%46th
Operating margin-119.5%46th
R&D / revenue17.7%54th
SBC / revenue10.7%54th

BIOMERICA INC (BMRA) reported revenue of $4.34M and net income of -$5.01M for the fiscal year ended 2026-08-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from BIOMERICA INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.

Income

BIOMERICA INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-08-31
Revenue$4.34M
Cost of revenue$4.30M
Gross profit$39.00K
Operating income-$5.43M
Net income-$5.01M
Research & development$782.00K
Weighted-average diluted sharesUnavailable
Pretax income-$4.98M
Income tax expense$25.00K
Diluted EPSUnavailable
Selling, general & administrative$4.69M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

BIOMERICA INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-08-31
Cash & equivalents$2.73M
Total assets$8.07M
Current assets$5.41M
Total liabilities$4.42M
Current liabilities$2.84M
Total equity incl. NCI$3.65M
Temporary (mezzanine) equityUnavailable
Inventory$1.63M
Accounts receivable$897.00K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

BIOMERICA INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-08-31
Operating cash flow-$3.96M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$3.64M
Net change in cash-$320.00K
Stock-based compensation$477.00K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$72.00K

Derived

BIOMERICA INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-08-31
Free cash flowUnavailable
Gross margin0.9%
Operating margin-125.2%
FCF marginUnavailable
SBC / revenue11.0%
Current ratio1.91x
Revenue YoY growth-11.2%
Net margin-115.5%
R&D / revenue18.0%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BMRA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-15View SEC filing
10-K/A · Filed 2026-09-28View SEC filing
10-K · Filed 2026-08-31View SEC filing
10-Q · Filed 2026-04-13View SEC filing
10-Q · Filed 2026-01-14View SEC filing
10-Q · Filed 2025-10-14View SEC filing

Companies in the same industry

ACHV AWHL BZYR CDIO CLDX ICCC IDXX IMDX LNTH MYGN NEOG NTLA

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.